Endometrial safety: a key hurdle for selective estrogen receptor modulators in development

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Selective estrogen receptor modulators (SERMs) possess tissue-specific agonist/antagonist properties.
• Tamoxifen, a widely used SERM for breast cancer, carries risks of endometrial hyperplasia and malignancy due to uterine ER agonist activity.
• Endometrial safety is a critical factor in SERM development, driving the search for improved benefit-risk profiles.

Purpose of the Study:

• To review the endometrial safety profiles of various SERMs, including established and investigational agents.
• To compare the effects of different SERMs on the uterus in the context of postmenopausal osteoporosis and breast cancer prevention.

Main Methods:

• Review of clinical trial data and published literature on SERMs.
• Comparative analysis of endometrial outcomes associated with tamoxifen, raloxifene, lasofoxifene, ospemifene, bazedoxifene, and arzoxifene.

Main Results:

• Raloxifene demonstrates neutral uterine effects.
• Lasofoxifene shows efficacy but is linked to increased vaginal bleeding and endometrial changes.
• Bazedoxifene exhibits efficacy in preventing osteoporosis without adverse endometrial effects.

Conclusions:

• Newer SERMs are being developed for improved tissue specificity and endometrial safety.
• Bazedoxifene presents a favorable endometrial safety profile for postmenopausal osteoporosis.
• Further research is needed to fully elucidate the long-term endometrial safety of emerging SERMs.